16 results about "Ginkgolide" patented technology

The invention provides application of ginkgo terpene lactones, bilobalide or stereoisomers thereof in preparation of drugs for preventing or treating hyperlipidemia and hyperlipidemia complications.

The present application belongs to the technical field of medicine, and relates to derivatives of carboxylic acid groups introduced by 10-position hydroxyl in the structure of ginkgolide B and ester derivatives of the carboxylic acid groups, and pharmaceutically acceptable organic or inorganic salts, as shown in formula 1 and formula 2. The present application takes ginkgolide B as a matrix, and is chemically modified to improve the solubility, increase the bioavailability, and enhance the curative effect of ginkgolide B. The prepared compound and carboxylic acid salt thereof have significant platelet activating factor antagonism, anticoagulation effect, and acute cerebral ischemia effect, and can be used for preparing medicines for preventing and treating ischemic stroke, thrombosis, angina pectoris, cardiopulmonary infarction, and diseases related to platelet activating factor, such as inflammation, asthma, and the like.

This invention provides a composition of Ginkgo biloba extract and its preparation method. The composition consists of Ginkgo biloba extract (calculated as total flavonol glycosides) and dipyridamole in a dosage ratio of 10:4. The preparation method can significantly improve product yield, reduce production costs, and significantly increase the content of the main components of the produced Ginkgo biloba extract, namely total flavonol glycosides and terpene lactones. It can also reduce the content of poorly water-soluble ginkgolides and harmful impurities such as ginkgolic acid, control its microbial level, and improve the stability and safety of the Ginkgo biloba extract preparation product of this invention.

The present disclosure relates to oral compositions that include at least two agents selected from: agents that increase the concentration of glutamate; agents that increase dopamine production; agents that increase the concentration of brain-derived neurotrophic factor (BDNF); NMDA and / or AMPA receptor modulators; and acetylcholinesterase inhibitors. In son embodiments, a composition as provided herein includes D-glutamine present in an amount of about 20% to about 30% w / w of the composition; ginkgolide B present in an amount of about 0.1% to about 0.4% w / w of the composition; phosphatidylserine present in an amount of about 65% to about 80% w / w of the composition; and ascorbic acid present in an amount of about 0.5% to about 2.5% w / w of the composition. Such compositions are useful for improving memory and / or focus.

The invention provides application of bilobalide B in inhibiting cerebral ischemia reperfusion injury caused by ferroptosis, and relates to the field of cerebral ischemia reperfusion injury. According to the application, ginkgolide B inhibits ferroptosis by regulating an Nrf2 / H0-1 pathway so as to improve cerebral ischemia reperfusion injury, regulation of Nrf2 / H0-1 promotes nuclear translocation of Nrf2 and up-regulates expression of a downstream antioxidant gene HO-1 so as to relieve spinal cord injury by inhibiting ferroptosis, and up-regulation of the expression of the downstream antioxidant gene HO-1 is that when cells are stimulated by hypoxia, the expression of the downstream antioxidant gene HO-1 is inhibited so as to inhibit the ischemia reperfusion injury. And the Nrf2 is dissociated from the Keap1 and is translocated to a cell nucleus. The action mechanism of the ginkgolide B for inhibiting the ferroptosis process and improving the CIRI by regulating and controlling an Nrf2 / HO-1 signal channel is explored, and a research strategy of combining bioinformatics prediction and experimental verification is adopted, so that a foundation is laid for deeply analyzing the neuroprotective action mechanism of the ginkgolide B; and a new research thought and a potential target spot are provided for developing a novel ginkgo leaf-related active ingredient medicine.

The invention discloses application of bilobalide in inhibiting migration and invasion of ovarian cancer cells, and relates to the technical field of biological medicines. Application of bilobalide in preparation of drugs for inhibiting migration and invasion of ovarian cancer cells; the concentration of the bilobalide is 5 [mu] M to 40 [mu] M. In the application of the bilobalide, the bilobalide shows an obvious growth inhibition effect on ovarian cancer cells and has no obvious influence on the survival rate of normal ovarian cells; in a concentration range of 5-40 [mu] M, bilobalide shows dose dependence on activity inhibition of SKOV3 and ID-8 cells, but has small influence on IOSE80 cells, and shows a good safety window; compared with a traditional chemotherapeutic drug, the bilobalide as a natural compound has better biocompatibility, and is expected to be capable of remarkably relieving common toxic and side effects such as myelosuppression and liver and kidney function impairment in clinical application.

The application provides a sugar alcohol solvent and its application in preparation of a product containing ginkgo leaf extract, and belongs to the technical field of food and health care products. The sugar alcohol solvent comprises xylitol, and the mass percentage of xylitol in the sugar alcohol solvent is 30-50%. The sugar alcohol solvent is safe and non-toxic, has simple preparation process and low cost, can be used as a solubilizing solvent for the ginkgo leaf extract, can improve the solubility of the ginkgo leaf extract without affecting the stability and biological activity of ginkgolides and ginkgo flavones in the ginkgo leaf extract, can be used as an intermediate purification solvent for preparation of ginkgolide monomers, is safe and non-toxic, and can be used as a new solvent for the ginkgo leaf extract to prepare a liquid oral ginkgo leaf extract, so that liquid health care is realized, and safe drug delivery is realized for diagnosis and treatment of cardiovascular and cerebrovascular diseases of special groups (such as diabetic patients).

The application provides ginkgolide bulk drug. The application further provides a preparation method of the ginkgolide bulk drug and application thereof. The ginkgolide and the preparation method thereof can obtain high-quality ginkgolide bulk drug through the preferred preparation steps and conditions. Compared with the ginkgolide prepared by a conventional method, the ginkgolide has stable quality, low unqualified rate and good consistency of different batches of bulk drugs.

The present application provides a kind of pharmaceutical composition for vulvar sclerosing lichen and its preparation method, the pharmaceutical composition includes active ingredient and pharmaceutically acceptable vulva local administration adjuvant, active ingredient is made of 0.005-0.02 parts of mometasone furoate, 0.05-0.3 parts of calcineurin inhibitor, 0.5-2 parts of paeoniflorin, 0.8-3 parts of asiaticoside, 0.3-1.5 parts of recombinant collagen, 0.2-1 part of ginkgolide B.The present application is aimed at the core pathogenesis of disease, constructs multi-target whole course of disease synergistic therapy system, can realize anti-inflammatory regulation, anti-fibrosis, basement membrane repair, microcirculation improvement simultaneously, low-dose strong effect, greatly reduce side effect and recurrence rate;Liposome targeted delivery technology is used, the stability of active ingredient is guaranteed, process controllable adaptation industrialization production, and clinical application prospect is wide.

The present invention relates to a synergistic composition for controlling headache disorders. The composition comprises Palmitoylethanolamide, Magnesium, and Ginkgolide B, along with pharmaceutically acceptable excipients. The invention addresses primary headache disorders, including migraine and tension-type headaches, which represent the majority of headache disorders. Palmitoylethanolamide exhibits analgesic and anti-inflammatory properties, down¬ regulating pro-inflammatory and nociceptive pathways. Magnesium contributes to the reduction of headache symptoms, while Ginkgolide B, derived from Ginkgo biloba, enhances the therapeutic effect. Animal studies have demonstrated the synergistic efficacy of this combination in reducing the frequency, duration, and severity of headache symptoms, both independently and when used with standard treatments.

The invention discloses a gene GbSAUR48 for promoting synthesis and biomass of bilobalide as well as a carrier, a protein and application of the gene GbSAUR48. The nucleotide sequence of the gene GbSAUR48 is shown as SEQ ID NO. 1. According to the invention, the GbSAUR48 gene specifically and highly expressed in the ginkgo biloba root reveals dual functions of the GbSAUR48 gene in promoting lateral root generation, improving overground and underground biomass and promoting bilobalide synthesis for the first time. The number of fibrous roots / lateral roots and the overall overground / underground biomass of the plant over-expressed with GbSAUR48 are remarkably increased, and meanwhile the content of active terpene lactones (GA and GB) is synchronously increased. The invention not only shows that the GbSAUR48 is a key gene for regulating and controlling the quality (medicinal quality) and yield (biomass) of the gingko, but also provides a new theoretical basis and a practical path for realizing double improvement of the medicinal value and the yield of the gingko through a molecular breeding means.

The invention relates to the technical field of medicines, in particular to application of ginkgo terpene lactone in preparation of medicines for prevention, treatment and / or adjuvant treatment of prostatic cancer. The ginkgo terpene lactone and a composition or extract thereof can inhibit cell proliferation of prostatic cancer cell lines, have a quality effect on prostatic cancer, and can be used for preparing medicines for preventing, treating and / or adjunctively treating prostatic cancer. The compound can be used for preparing medicines for treating prostatic cancer.

The invention relates to the technical field of plant genetic engineering, in particular to a ginkgo terpene synthase gene GbTPS13 and application of the ginkgo terpene synthase gene GbTPS13 in heterologous synthesis of a bilobalide precursor in tobacco. The nucleotide sequence of the ginkgo terpene synthase gene GbTPS13 is as shown in SEQ ID NO. 1, and the coded amino acid sequence is as shown in SEQ ID NO. 2; ginkgo biloba diterpene synthase GbTPS13 is identified in tobacco tissues, L-pimaric diene can be catalytically generated through overexpression of GbTPS13 in tobacco, the diterpene compound is a common precursor of bilobalide, and the method is used for constructing a tobacco chassis system capable of being used for synthesizing bilobalide. And a potential starting platform and basic framework are provided for complete and large-scale biosynthesis of bilobalide.

The application relates to application of ginkgo biloba lactone A in preparation of drugs against white spot syndrome, aiming at the problem that effective treatment drugs are still lacking for the destructive damage of white spot syndrome virus (WSSV) to aquatic crustaceans, and providing a new application of ginkgo biloba lactone A; through in-vitro experiment of Hpt cells of astacus leptodactylus and in-vivo feeding experiment of astacus leptodactylus, it is verified that the ginkgo biloba lactone A can significantly inhibit WSSV replication at a concentration of 100 muM; the astacus leptodactylus is fed with 40 mg / kg feed for 10 days, the survival rate after being infected with WSSV is increased by about 53.3%, meanwhile, the expression of immune-related genes is up-regulated, the apoptosis rate of blood cells is reduced, and the virus replication is significantly inhibited; a safe and efficient new drug for the prevention and control of WSSV in aquatic breeding is provided, and has important industrial application value.

The application discloses a kind of functionalization exosome-traditional Chinese medicine small molecule composite preparation T-pEXOs@GB and its preparation method and application.The composite preparation encapsulates ginkgolide B (GB) in the exosome of healthy plasma, and is functionally modified neuron target peptide RVG (DSPE-PEG-RVG) on its surface, so that it has brain targeting and oxygen supply functions.The preparation method provided by the application can efficiently and controllably prepare the composite preparation with uniform particle size and good stability.The T-pEXOs@GB composite preparation of the application can be targeted to deliver to brain ischemia and hypoxia injury area, significantly reduce oxidative stress and inflammatory response, reduce cerebral infarction volume, improve neurological deficit score, and improve the survival rate of animal model, and can be used to prepare drugs for preventing and treating acute high altitude cerebral hypoxia, ischemic stroke, neonatal hypoxic-ischemic encephalopathy and other cerebral ischemia and hypoxia injury, and has good market prospect.

The application discloses a kind of pharmaceutical composition for treating pulmonary fibrosis and application thereof, belong to biological medicine technical field.The ginkgolide K (GinK) raw material source of the present application is easy, preparation cost is low, with lower toxicity, as natural industrialization small molecule.Small molecule STING inhibitor C176 has the ability to inhibit STING signal and have positive effect on fibrosis endpoint, can clearly target inhibition STING signal.Ginkgolide K (GinK) and small molecule STING inhibitor C176 are combined to use, can improve histological lesions and down-regulate the expression of several fibrosis-related proteins, have obvious synergistic effect on histological improvement, fibrosis-related protein expression inhibition and other endpoints, so as to achieve the synergistic effect that single drug is difficult to achieve, and reduce the potential toxicity and cost problem brought by single drug high dose.